AvidinOX®, a product containing aldehyde groups, generated by ligand-assisted sugar oxidation of avidin by sodium periodate, maintains the capacity to bind biotin with very high affinity and exhibits the property to chemically link cellular and tissue proteins through Schiff's base formation thus residing in tissues for weeks. In recent studies, we have shown that AvidinOX exhibits much higher persistency in the skeletal muscle than native avidin. The aim of the present study is to evaluate whether AvidinOXbiotin interaction might be exploited to target biotinylated cells to an AvidinOX pre-treated muscle. To accomplish this we performed the following experiments: 1) The proliferation and differentiation properties of biotinylated C2C12 myoblasts were tested in vitro upon linkage to AvidinOX; 2) Bone marrow-derived cells (BMDC) were isolated from GFP positive transgenic mice [strain C57 BL/6-tg (UBC-GFP)] and after biotinylation (bBMDC) were intravenously administered to naive and MAVA+ (Mouse anti Avidin Antibody) C57/B6 mice previously injected with AvidinOX in a tibial muscle (TM). Localization efficiency of GFP+ bBMDC was evaluated on serial sections of-the AvidinOX-and vehicletreated (contra lateral limb) TM, 5 days after transplantation. Results show that biotinylated C2C12 cells, once linked to AvidinOX, maintain their proliferation and differentiation capacity, in vitro. Intravenous injection ofbiotinylated GFP+ bone marrow-derived cells leads to their specific and efficient localization in the AvidinOX-pre-treated, but not contra lateral muscle of both naive and MAVA+mice. The present data suggest a potential use of AvidinOX to improve tissue targeted delivery of biotinylated cells.
stem cells give rise to all blood cell types and have been shown to exhibit plasticity, while multipotent marrow stromal cells are the source of osteocytes, chondrocytes, and fat cells and have been shown to support and generate a large number of different cell types (10) .
A key point for an effective use of stem cell therapy relies on the cell capacity to home and long term engraft into the appropriated target tissue. However, in case of systemic cell delivery, spontaneous homing of cells to specific tissues was shown to be limited (11) .
Muscle regeneration represents one of the most important homeostatic process of adult skeletal muscle in which several factors are sequentially activated to maintain and preserve muscle structure and function. The major role in the growth, remodelling and regeneration is played by satellite cells, a quiescent population of myogenic cells that reside between the basal lamina and plasmalemma and are rapidly activated in response to appropriate stimuli (12) . Recently, it has been suggested that other "non-muscle" stem cell populations can participate in muscle regeneration and in some way contribute to maintain the pool of satellite cells (13) . These stem cell populations could either reside within muscle, or be recruited via the circulation in response to homing signals emanating from injured skeletal muscle. These populations include endothelial-associated cells, interstitial cells and bone marrow-derived side population cells.
However, muscle regeneration is severely compromised in several pathological conditions. It is likely that the restricted tissue repair program under pathological conditions is due to either progressive loss of stem cell populations or to missing signals that limit the damaged tissues to efficiently activate a regenerative program.
Indeed, even in a chronically regenerating environment as that of mdx (an X chromosomelinked myopathic mutant) dystrophic muscle, marrow-derived stem cells are unable to give rise to dystrophin-positive muscle fibers in clinically relevant numbers (14) . It is tempting to speculate that the poor recruitment of hematopoietic stem cells (HSC) into the muscle ofpathological mouse models may be the major obstacle for muscle regeneration. In addition, it is also possible that the pathologic muscle does not provide sufficient selective advantage to the recruited cells to rescue the altered muscle phenotype.
It was recently described that chemically oxidized avidin named AvidinOX®, when injected, is able to persist for weeks in tissues acting as a stable receptor for biotinylated moieties (15) (16) . We showed that AvidinOX can be useful for tissue targeted delivery of radioactive biotin to inoperable tumors (17) and the long tissue residence ofAvidinOX was proved to be due to its peculiar capacity to form Schiff's bases with tissue proteins (18) . Tissue linkage induces a transient local inflammatory response, more evident in animals pre-immunized against avidin (19) (20) . In the present study, we show that AvidinOX, injected into the muscle of narve or avidin immunized mice, is able to improve tissue targeted delivery of intravenously transplanted biotinylated bone marrow-derived cells.
MATERIALS AND METHODS
C2C12 mouse myoblast culture and in vitro uptake of biotinylated C2C12 cells C2C12 cells were obtained from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum. Mouse myoblast C2C12 cells were biotinylated using Sulfo-NHS-LC-biotin (Thermo Scientific, Rockford, USA) following the procedure suggested by the manufacturer, and using different concentrations of biotin: 500-100-50 Ilg! 25x10 6 cells. After biotinylation, cells were incubated with Streptavidin FITC (BD Pharmingen'>', San Diego, California, USA) and analyzed by Cytofluorimetry to confirm biotinylation.
Twelve well tissue culture plates were coated with type 1 collagen (BD Biosciences) (50llg/ml in DMEM). After washings with PBS, collagen coated wells were incubated for 2 h at room temperature with 1 ml of AvidinOX (lOOIlg!ml in PBS). After washings, the residual aldehyde groups of AvidinOX were blocked by incubation with 100 mM semicarbazide (Sigma-Aldrich, Milano, Italy) pH 7.4, 1 h at room temperature under shaking. After repeated washings with PBS, biotinylated C2C12 cells were added under sustained agitation (l O'rwell) at 4°C for 5 mins. Cells were observed by microscopy after 0.3 and II days.
Protein extraction and immunoblotfor myosin detection
C2C12 cells were washed with phosphate-buffered saline and lysed with a lysis buffer (50 mM Tris-HCI, pH 7.4, 1% wt/vol Triton X-lOO, 0.25% sodium deoxycholate, 150 mM sodium chloride, 1 mM PMSF, 1 ug/ml of each aprotinin, leupeptin, pepstatin, 1 mM sodium orthovanadate, 1 mM sodium fluoride). Equal amounts of protein from each lysate were separated in SDS polyacrylamide gel and transferred onto a hybond C extra nitrocellulose membrane. Filters were blotted with antibodies against MF-20 (Hybridoma bank) and antitubulin (Sigma).
Mice Immunization by native avidin
Female C57BLl6 mice (Harlan Udine, ITALY) were immunized with native avidin (Tecnogen SpA, Caserta, Italy) at a concentration of 1.0 mg/200~1 of saline per mouse, by a single intravenous (i.v.) administration. MAVA titres were determined by ELISA as previously described (20) .
Bone marrow transplantation
Bone marrow stem cells were isolated from femur and tibia of 6-week-old GFP positive transgenic mice [strain C57BLl6-tg (UBC-GFP), Jackson Laboratory, Bar Harbor, Maine, USA]. After biotinylation at different biotin/cell ratio (1000-50-5-0.5~g/ 25x10 6 cells) by Sulfo-NHS-LC-biotin, according to the manufacturer's instructions (Thermo Scientific, Rockford, USA), bone marrow cells were incubated with streptavidin PE (BD PharmingenTM, San Diego, Ca, USA) and analyzed by cytofluorimetry to confirm biotinylation and select the optimal 'biotin:cell ratio for subsequent in vivo experiments. Four MAVA+ and 4 naive female C57BLl6 mice (Harlan, Udine, Italy) were treated with AvidinOX (30~L of 3mg/mL) by 5-6 intramuscular injections (left anterior tibiae). The same volumes of vehicle (10 mM sodium acetate pH 5.5) were i.m. injected into the right anterior tibiae. Twenty-four hours later, mice were i.v. injected, via the tail vein, with 5xI0 6GFP+ bBMDCs, in 200~L of saline. Five days after bBMDC transplantation, the mice were sacrificed and the muscles of the left and right tibiae collected, cryopreserved and serial sections analyzed for fluorescence.
Immunofluorescence
Immunofluorescence was carried out on tissue cryosections of mouse limb muscles injected, 48 hours previously, with avidin or AvidinOX. Muscle cryosections (3-6 sections for each tibia) were incubated with a mouse anti-avidin antibody (Sigma-Aldrich) followed by goat anti-mouse Alexa Fluor" 488 (Molecular Probes) or mounted with DAPI. Images were acquired by Eclipse 80 (Nikon) equipped with a digital camera.
Fluorescence analysis
Cryosections (3-6 sections for each tibialis anterior muscle) of AvidinOX or vehicle-pretreated limbs from GFP+ bBMDC transplanted mice were embedded in tissue freezing medium and snap frozen in nitrogen-cooled isopentane. Frozen muscle sections of 7 urn were used for fluorescence analysis to reveal the presence of GFP+ . cells. DAPI mounted serial sections were used to identify nuclei. Inverted microscope (Axioskop 2 plus; Carl Zeiss Microimaging, Inc) using 20X or 40X lenses was used and images were processed using Axiovision 3.1.
RESULTS

Tissue localization ofAvidinOX®
We confirmed, by immunofluorescence, the stronger and more homogenous distribution of AvidinOX compared to avidin in the TA muscle of mice administered, 48 hours previously, with the two proteins. Interestingly, tissue localization of AvidinOX and avidin appeared to be in the stroma surrounding cells (Fig. 1 , A and C). Serial tissue sections from AvidinOX or avidin injected muscles were mounted with DAPI ruling out AvidinOX and avidin autofluorescence (Fig. 1, B and D, respectively). We postulated that such highly efficient and homogenous tissue localization of AvidinOX could be exploited to target biotinylated cells to the muscle.
In vitro analysis of the proliferation and differentiation potential of AvidinOX®-bound biotinylated C2C12 cells-
Before investigating whether the intra-tissue administration of AvidinOX could enhance tissue targeting of circulating biotinylated cells within the treated muscle, we deemed important to rule out the possible interference of AvidinOX anchorage on proliferation and differentiation of biotinylated cells. Therefore, we performed an in vitro test with biotinylated C2Cl2 cells which represent a widely employed model to investigate myogenic differentiation. FACS analysis showed that 100 ug biotin/Zfix l O" cells was a sufficient ratio for biotinylation of this cell type ( Fig. 2A) . After biotinylation, cells were incubated in vitro on AvidinOX coated plates. The condition used in the experiment (5' high shacking at +4DC) was set up to prevent the spontaneous adhesion of C2Cl2 cells to the substrate while allowing the linkage of biotinylated C2C12 cells to AvidinOX. Results indicate that AvidinOX-bound biotinylated C2Cl2 
. In vitro analysis ofbiotinylated C2CI2 cells. A) FACS analysis ofC2CI2 wild type cells (violet) or C2CI2 cells biotinylated with Sulfo-NHS-LC Kit, using different concentrations of biotin: cells ratio of 500 (blue)-IOO (pink)-50 (green) Ilg/25x106 cells. Biotinylated cells were analyzed after incubation with streptavidin FITC for 30 minutes. B)
Twelve wells tissue culture plates were coated with collagen and then incubated with AvidinOXfollowed by semicarbazide to prevent Schiff's base formation between AvidinOXand C2CI 2 membrane proteins. After repeated washings with PBS, biotinylated C2CI2 mouse myoblast cells were added under sustained agitation at 4°Cfor 5 minutes . Cells were observed by microscopy after 0, 3 and II days. No binding ofbiotinylated C2CI2 cells was observed in collagen coated wells nor in biotin saturated AvidinOX wells. Not biotinylated C2CI2 did not bind AvidinOX (data not shown). C) Western blot analysis of protein lysates from untreated (control:cnt) and AvidinOX-bound (AvidinOX) C2CI2 cells analyzed after 4 days of culture. Myosin was detected with MF-20 antibody. Tubulin was used to verify equal loading of the protein samples. Biotinylation was evaluated after incubation with streptavidin PEfor 30 minutes. 
Fig. 4. In vivo localization ofintravenously injected biotinylated GFr cells in AvidinOX-pretreatedmice. A) Fluorescence analysis ofmuscle sections from a MAYA+ mouse treated in the limb with AvidinOX and injected intravenously, after 24 hours, with biotinylated GFr bone marrow-derived cells. 5 days after transplantation. B) Serial section as in (A) but
In vivo localization of intravenously injected biotinylated bone marrow cells in mice i.m. pretreated with AvidinOX®
It is known that muscle damage is the prerequisite to mobilize non-muscle stem cells and to activate homing signals, namely growth factors and chemokines, necessary to recruit circulating stem cells toward the injured muscle. This is probably due to the activation ofthe inflammatory response, which is clearly a critical component of muscle physiology, and it is an important phase in the regenerative process (21) .
Taking into account our previous observation that AvidinOX induces an immunogenic response and consequently a local transient inflammatory reaction at the injection site, especially in pre-immunized mice, but without affecting its safety and efficacy (20) , we envisaged to induce the inflammatory response by i.m. injectingAvidinOX into both nalve and avidin immunized mice. Mice were immunized with native avidin and their resulting mouse antiavidin antibody (MAVA) titres (tested on AvidinOX) were about I: 1000 (serum dilution to obtain 1.0 OD in ELISA). In our experimental system, GFP+ BMDCs isolated from GFP transgenic mice were biotinylated and FACS analysis showed that 50 ug biotin/Zfix IO" cells was the optimal ratio for the biotinylation of this cell type (Fig. 3) .
Biotinylated GFP+ BMDCs were intravenously administered to naive or MAVA+ mice, pre-treated, 24 hours previously, with AvidinOX or vehicle into the left and right TA muscles, respectively. Tissue localization of GFP+ bBMDCs was examined on tissue cryosections, 5 days after transplantation.
Presence of a higher number of GFP+ bBMDC in the AvidinOX-treated compared to vehicle-treated muscle ofMAVA+ mice was observed (Fig. 4 , A and C, respectively). Serial sections ofthe AvidinOX and vehicle treated muscles were mounted with DAPI confirming, in the AvidinOX treated muscle, a higher number of cell nuclei (Fig. 4, Band D, respectively) . Similar results were obtained in naive mice (data not shown).
DISCUSSION
A major obstacle to the effective implementation of cellular therapies, that might be useful to address serious diseases and tissue regeneration, is the inability to target, with high efficiency, a large number of viable cells to the tissue of interest and to keep them therein. Repeated systemic injections are necessary to remedy and minimize these problems.
Unfortunately, the homing efficiency of systemically infused stem cells to the target site is low (usually less than 1%) due to their loss of relevant surface adhesion molecules and cytokine receptors. Many have tried to improve this limiting aspect, trying to engineer mesenchymal stem cells, developing a platform technology to chemically attach cell adhesion molecules to the cell surface to make them able to do rolling, adhere, proliferate and differentiate into tissues of interest (22) .
Recently, we showed that an oxidized avidin, named AvidinOX, can be useful to efficiently deliver biotinylated moieties to AvidinOX-treated tissues. Therefore, we postulated that biotinylated cells could also be delivered. In the present study, we show in vitro that the anchorage of biotinylated C2CI2 cells on immobilized AvidinOX does not impair proliferation and differentiation of such myogenic precursors. In in vivo studies, we found that to improve the delivery of bone marrow cells, it is not necessary to engineer the cell surface with adhesion molecules, but it is sufficient to biotinylate cells having pre-conditioned the target tissue (not necessarily inflamed) with AvidinOX. In particular, we observed that the i.m. treatment ofnaive (absence of inflammatory chemoattractant signals) or MAVA+ (presence of inflammatory chemoattractant signals) mice with AvidinOX is a condition favoring the localization, in the treated muscle, of intravenously injected, bone marrow-derived biotinylated cells. The result in naive mice is of interest as it might be speculated that distribution of stem cells in tissues occurs also in the absence of a strong danger signal. On the other hand, the result in MAVA+ mice is of relevance in a prospective clinical use of AvidinOX as it suggests that anti-avidin antibodies, known to spontaneously occur in human at low titre (19) , will not block the binding ofbiotinylated cells.
Interestingly, the GFP+ biotinylated cells were observed in the interstitium, a localization where the i.m. injected AvidinOX had also been found (Fig.  I) . This observation is of particular interest because the interstitium represents the site where stem cells can directly participate in muscle growth or muscle regeneration after a trauma (23) .
Overall, the present work suggests that AvidinOX could be used to promote targeted delivery of biotinylated stem cells in the muscle. The possibility to use AvidinOX to anchor biotinylated cells to tissues might be of particular therapeutic relevance for those diseases in which it is important to enhance persistence of stem cells participating in regeneration and/or in the maintenance of a differentiated phenotype.
